Overall, our review of the literature shows that SGLT-2 inhibitors can reduce the risk of cardiovascular death, all-cause mortality, and heart failure hospitalization when used in the treatment of heart failure. Most meta-analysis studies support the use of SGLT-2 inhibitors in the treatment of heart failure as SGLT-2 inhibitors are also linked with reduced serious adverse effects; however, its use in patients with severely impaired renal function remains an enigma. Here, SLC5A2 is linked to heart failure.